Physician profile
Robert Moghimi
NPI 1184679664
$13,280.91
in general payments reported to CMS, 2019-2025
35 companies · $1,892 in 2025
The $1,892 reported for 2025 was more than what 78% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $919 · 2020: $713 · 2021: $1,649 · 2022: $3,062 · 2023: $2,715 · 2024: $2,331 · 2025: $1,892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,938.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,938.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $7,231.67 | 2019-2025 | |
| Janssen Biotech, INC. | $1,555.25 | 2019-2025 | Stelara, Tremfya, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $839.91 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Celgene Corporation | $484.98 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $426.94 | 2019-2023 | Entyvio |
| Gilead Sciences, INC. | $274.07 | 2019-2023 | |
| Madrigal Pharmaceuticals | $271.28 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $230.70 | 2022-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $207.43 | 2024-2025 | Vowst, Zenpep |
| Allergan, INC. | $186.14 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $172.17 | 2022-2024 | Dupixent |
| Phathom Pharmaceuticals, INC. | $148.13 | 2024-2025 | Voquezna |
| Boston Scientific Corporation | $147.44 | 2022-2025 | Spyglass, Resolution 360 Clip, General - Biliary Devices |
| Lilly USA, LLC | $132.14 | 2023-2025 | Omvoh |
| Pfizer INC. | $116.28 | 2022-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $109.37 | 2023 | Xarelto |
| Nestle Healthcare Nutrition INC. | $104.65 | 2020-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.24 | 2023-2024 | Cyltezo |
| Merck Sharp & Dohme LLC | $77.35 | 2019-2024 | Dificid |
| Vivus LLC | $67.87 | 2024-2025 | Pancreaze |
| Genzyme Corporation | $56.08 | 2024 | |
| Ferring Pharmaceuticals INC. | $55.60 | 2020-2023 | Rebyota |
| Qol Medical, LLC | $48.70 | 2024-2025 | Sucraid, Sucraid |
| Intercept Pharmaceuticals, INC. | $42.64 | 2020-2024 | |
| Ironwood Pharmaceuticals, INC | $41.94 | 2021-2024 | |
| Saluda Medical Americas, INC. | $41.83 | 2025 | Evoke |
| Evoke Pharma, INC. | $24.46 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $23.29 | 2024 | Exparel, Iovera, Zilretta |
| Redhill Biopharma INC. | $21.06 | 2020 | |
| Biocon Biologics INC | $16.78 | 2025 | Yesintek |
| Novo Nordisk INC | $15.90 | 2025 | Wegovy |
| Endogastric Solutions, INC | $6.62 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Moghimi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.